Yehui M. Shi
Key Laboratory Of Breast Cancer Prevention And Therapy, Ministry Of Education
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial.
Journal: Cancer research and treatment
Published: April 12, 2026
Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study.
Journal: Frontiers in pharmacology
Published: November 30, 2025
The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.
Journal: Cancers
Published: November 19, 2025
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.
Journal: Nature communications
Published: August 28, 2025
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.
Journal: Breast (Edinburgh, Scotland)
Published: March 19, 2025
Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 10, 2025
DNAJC24 suppresses breast cancer malignancy and serves as a prognostic biomarker.
Journal: Cancer cell international
Published: February 07, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.
Journal: Signal transduction and targeted therapy
Published: September 13, 2024
Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: July 01, 2024
PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer.
Journal: Frontiers in cell and developmental biology
Published: May 09, 2024
Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2-positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment.
Journal: Cancer innovation
Published: April 22, 2024
Last Updated: 09/26/2026